Comprehensive Analysis of Single-cell RNA and Bulk RNA Sequencing Based on M2 Tumor-associated Macrophage and Angiogenesis-related Genes to Assess Prognosis and Therapeutic Response in Lung Adenocarcinoma

Overview

Journal Heliyon

Specialty Social Sciences

Date 2024 Aug 16

PMID 39148979

Authors

Anbang Liu

Gengqiu Liu

Xiaohuai Wang

Dongqing Yan

Junhang Zhang

Li Wei

Affiliations

Soon will be listed here.

Abstract

M2 tumor-associated macrophage (M2 TAM), a crucial component of the tumor microenvironment, has a significant impact on tumor invasion and metastasis in the form of angiogenesis for lung adenocarcinoma (LUAD). In this study, both single-cell RNA and bulk RNA sequencing data were analyzed to identify 12 M2 TAM and angiogenesis-related genes (OLR1, CTSL, HLA-DPB1, NUPR1, ALOX5, DOCK4, CSF2RB, PTPN6, TNFSF12, HNRNPA2B1, NCL, and BIRC2). These genes were used to construct a prognostic signature, which was subsequently validated using an external cohort. Moreover, the immune profile analysis indicated that the low-risk group exhibited a distinct immune cell infiltration and relatively active status. Importantly, the prognostic signature was closely associated with PD-1, CTLA4, tumor mutation burden, and anti-cancer drug sensitivity. In summary, this study proposes a new prognostic signature for patients with LUAD based on M2 TAM and angiogenesis-related genes. The signature forecasts the prognosis of LUAD by an independent manner, reveals the potential molecular mechanisms involved in tumor immune-related functions, and offers appropriate clinical strategies for the treatment of patients with LUAD.

References

Petty A, Yang Y . Tumor-associated macrophages: implications in cancer immunotherapy. Immunotherapy. 2017; 9(3):289-302. PMC: 5619052. DOI: 10.2217/imt-2016-0135. View

Goc J, Germain C, Vo-Bourgais T, Lupo A, Klein C, Knockaert S . Dendritic cells in tumor-associated tertiary lymphoid structures signal a Th1 cytotoxic immune contexture and license the positive prognostic value of infiltrating CD8+ T cells. Cancer Res. 2013; 74(3):705-15. DOI: 10.1158/0008-5472.CAN-13-1342. View

Paucek R, Baltimore D, Li G . The Cellular Immunotherapy Revolution: Arming the Immune System for Precision Therapy. Trends Immunol. 2019; 40(4):292-309. DOI: 10.1016/j.it.2019.02.002. View

Zhong R, Chen D, Cao S, Li J, Han B, Zhong H . Immune cell infiltration features and related marker genes in lung cancer based on single-cell RNA-seq. Clin Transl Oncol. 2020; 23(2):405-417. DOI: 10.1007/s12094-020-02435-2. View

Yarchoan M, Hopkins A, Jaffee E . Tumor Mutational Burden and Response Rate to PD-1 Inhibition. N Engl J Med. 2017; 377(25):2500-2501. PMC: 6549688. DOI: 10.1056/NEJMc1713444. View

Hanzelmann S, Castelo R, Guinney J . GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinformatics. 2013; 14:7. PMC: 3618321. DOI: 10.1186/1471-2105-14-7. View

Papalexi E, Satija R . Single-cell RNA sequencing to explore immune cell heterogeneity. Nat Rev Immunol. 2017; 18(1):35-45. DOI: 10.1038/nri.2017.76. View

Havel J, Chowell D, Chan T . The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy. Nat Rev Cancer. 2019; 19(3):133-150. PMC: 6705396. DOI: 10.1038/s41568-019-0116-x. View

DeNardo D, Ruffell B . Macrophages as regulators of tumour immunity and immunotherapy. Nat Rev Immunol. 2019; 19(6):369-382. PMC: 7339861. DOI: 10.1038/s41577-019-0127-6. View

10.

Amelio I, Melino G . Context is everything: extrinsic signalling and gain-of-function p53 mutants. Cell Death Discov. 2020; 6:16. PMC: 7090043. DOI: 10.1038/s41420-020-0251-x. View

11.

Blandino G, Di Agostino S . New therapeutic strategies to treat human cancers expressing mutant p53 proteins. J Exp Clin Cancer Res. 2018; 37(1):30. PMC: 5815234. DOI: 10.1186/s13046-018-0705-7. View

12.

Wu T, Wu X, Wang H, Chen L . Immune contexture defined by single cell technology for prognosis prediction and immunotherapy guidance in cancer. Cancer Commun (Lond). 2019; 39(1):21. PMC: 6471962. DOI: 10.1186/s40880-019-0365-9. View

13.

Bailey C, Negus R, Morris A, Ziprin P, Goldin R, Allavena P . Chemokine expression is associated with the accumulation of tumour associated macrophages (TAMs) and progression in human colorectal cancer. Clin Exp Metastasis. 2007; 24(2):121-30. DOI: 10.1007/s10585-007-9060-3. View

14.

Taube J, Galon J, Sholl L, Rodig S, Cottrell T, Giraldo N . Implications of the tumor immune microenvironment for staging and therapeutics. Mod Pathol. 2017; 31(2):214-234. PMC: 6132263. DOI: 10.1038/modpathol.2017.156. View

15.

Yang X, Tang Z, Zhang P, Zhang L . [Research Advances of JAK/STAT Signaling Pathway in Lung Cancer]. Zhongguo Fei Ai Za Zhi. 2019; 22(1):45-51. PMC: 6348154. DOI: 10.3779/j.issn.1009-3419.2019.01.09. View

16.

Zou Z, Tao T, Li H, Zhu X . mTOR signaling pathway and mTOR inhibitors in cancer: progress and challenges. Cell Biosci. 2020; 10:31. PMC: 7063815. DOI: 10.1186/s13578-020-00396-1. View

17.

Friedman J, Hastie T, Tibshirani R . Regularization Paths for Generalized Linear Models via Coordinate Descent. J Stat Softw. 2010; 33(1):1-22. PMC: 2929880. View

18.

Mayakonda A, Lin D, Assenov Y, Plass C, Koeffler H . Maftools: efficient and comprehensive analysis of somatic variants in cancer. Genome Res. 2018; 28(11):1747-1756. PMC: 6211645. DOI: 10.1101/gr.239244.118. View

19.

Viallard C, Larrivee B . Tumor angiogenesis and vascular normalization: alternative therapeutic targets. Angiogenesis. 2017; 20(4):409-426. DOI: 10.1007/s10456-017-9562-9. View

20.

Tata P, Rajagopal J . Plasticity in the lung: making and breaking cell identity. Development. 2017; 144(5):755-766. PMC: 5374348. DOI: 10.1242/dev.143784. View